Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer

Area of Science:

• Oncology and Immunology
• Cancer Biology
• Epigenetics

Background:

• Triple-negative breast cancer (TNBC) lacks targeted therapy options due to its aggressive nature, heterogeneity, and resistance.
• TNBC exhibits variable immunogenicity, often employing immune evasion strategies like T-cell exhaustion and immune checkpoint activation.
• Molecular subtyping reveals distinct features influencing therapeutic response, highlighting the need for tailored treatments.

Purpose of the Study:

• To review the complex interplay between TNBC molecular heterogeneity, immune evasion, and epigenetic regulation.
• To explore how epigenetic mechanisms influence immune escape and immunotherapy resistance in TNBC.
• To highlight the potential of combining epigenetic therapies with immunotherapy and chemotherapy for TNBC.

Main Methods:

• Literature review synthesizing multi-omics data, immunological findings, and epigenetic studies in TNBC.
• Analysis of immune evasion mechanisms, including tumor microenvironment remodeling and immune checkpoint pathways.
• Examination of epigenetic regulation of immune-related genes and the impact of epigenetic drugs.

Main Results:

• TNBC heterogeneity impacts immunogenicity and therapeutic outcomes.
• Epigenetic silencing of key immune components contributes to immune evasion and resistance.
• Pharmacological modulation of epigenetic regulators can restore antitumor immunity and enhance treatment response.

Conclusions:

• Epigenetic therapies hold promise for overcoming immunotherapy resistance in TNBC.
• Targeting epigenetic mechanisms can re-sensitize tumors to immunotherapy and chemotherapy.
• Further research into epigenetic-immune interactions is crucial for developing subtype-specific TNBC treatments.